title: Increased CCL22 expression in psoriatic skin predicts a good response to infliximab therapy.
authors.affiliation: Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kusumoto
authors.forename: I
authors.initials: I
authors.lastname: Kajihara
authors.forename: E
authors.initials: E
authors.lastname: Nagamoto
authors.forename: K
authors.initials: K
authors.lastname: Makino
authors.forename: A
authors.initials: A
authors.lastname: Ichihara
authors.forename: J
authors.initials: J
authors.lastname: Aoi
authors.forename: T
authors.initials: T
authors.lastname: Johno
authors.forename: T
authors.initials: T
authors.lastname: Makino
authors.forename: S
authors.initials: S
authors.lastname: Fukushima
authors.forename: M
authors.initials: M
authors.lastname: Jinnin
authors.forename: H
authors.initials: H
authors.lastname: Ihn
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D054422:Chemokine CCL22 / Q000378:metabolism*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012333:RNA, Messenger / Q000378:metabolism; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C515482:CCL22 protein, human; D054422:Chemokine CCL22; D003879:Dermatologic Agents; D012333:RNA, Messenger; D000069285:Infliximab